News

Heritage Foundation said it is "likely" that the Biden administration will implement the tracking policy across the government.

Sen. Ted Cruz, R-Texas, introduces legislation to prohibit federal government from limiting state access to monoclonal antibody treatments.

"I have asked multiple times for the specific misrepresentations," says doctor Meryl Nass, who is associated with vaccine skeptic Robert F. Kennedy Jr.

Manchin supports the legislation but not changes to Senate rules essentially allowing it to pass by a simple majority

Jed S. Rakoff is frustrated that white-collar criminals go free while the indigent do time.

'The no-cash bail policy and extended timeframe for suspects to appear in court is causing re-victimization to UP by these same criminals,' UP official Adrian Guerrero says,

Mounting evidence of irregularities and rigged rules has emerged through state and local investigations, court decisions, financial disclosure, and audits in the 14 months since the election.

Another voice banished from the town square...

No warning...

Operation Warp Speed brought to market in the United States two mRNA vaccines, produced by Pfizer and Moderna. Interim data suggested high efficacy for both of these vaccines, which helped legitimize Emergency Use Authorization (EUA) by the FDA. However, the exceptionally rapid movement of these vaccines through controlled trials and into mass deployment raises multiple safety concerns. In this review we first describe the technology underlying these vaccines in detail. We then review both components of and the intended biological response to these vaccines, including production of the spike protein itself, and their potential relationship to a wide range of both acute and long-term induced pathologies, such as blood disorders, neurodegenerative diseases and autoimmune diseases. Among these potential induced pathologies, we discuss the relevance of prion-protein-related amino acid sequences within the spike protein. We also present a brief review of studies supporting the potential for spike protein “shedding”, transmission of the protein from a vaccinated to an unvaccinated person, resulting in symptoms induced in the latter. We finish by addressing a common point of debate, namely, whether or not these vaccines could modify the DNA of those receiving the vaccination. While there are no studies demonstrating definitively that this is happening, we provide a plausible scenario, supported by previously established pathways for transformation and transport of genetic material, whereby injected mRNA could ultimately be incorporated into germ cell DNA for transgenerational transmission. We conclude with our recommendations regarding surveillance that will help to clarify the long-term effects of these experimental drugs and allow us to better assess the true risk/benefit ratio of these novel technologies.

Moderna has halted a patent dispute with the U.S. federal government.